Covishield Approval EMA | Covishield: Poonawalla confident of getting EMA approval for ‘Covishield’ in 1 month. SII CEO Adar Poonawalla Confident of getting EMA approval for Covishield in a month

Covishield Approval EMA | Covishield: Poonawalla confident of getting EMA approval for ‘Covishield’ in 1 month. SII CEO Adar Poonawalla Confident of getting EMA approval for Covishield in a month

Covishield

Kovid-19 Vaccine Covishield &nbsp

New Delhi: Vaccine maker Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla said on Wednesday that the company is confident of getting approval from the European Medicines Agency (EMA) for its Kovid-19 vaccine Covishield in a month.

Poonawalla said at the India Global Forum 2021, “The EMA is absolutely right to ask us to apply, which we have done through our partner AstraZeneca a month ago and that process takes its own time. The approval process with UK MHRA, WHO also took time and we have applied to EMA.

‘Our product is more or less similar to AstraZeneca’

“We are confident that in a month’s time EMA will clear Covishield. There is no reason not to do so, as this is based on AstraZeneca data and our product is more or less identical to AstraZeneca and has been approved by WHO, UK MHRA. So it is only a matter of time.’

Related news

The issue has arisen because the issue is yet to be resolved and when India is out of the list of sanctions and when citizens want to travel, they should not be denied access to a country just because they have a Covidshield certificate. On the issue of exemption of intellectual property rights on vaccines to increase supply, Poonawalla said that exemption of intellectual property rights is probably not going to solve the immediate shortage of vaccines. However, it is a good strategy in the long term to be prepared for future pandemics, he added.

See also  India reports 1.96 lakh new COVID-19 cases, lowest single-day tally since 14 April-India News , Technomiz

‘The decision to stop exports was particularly stressful’

Poonawalla said the decision to halt exports was particularly stressful, ‘because it was not only our ally AstraZeneca that needed vaccines for other parts of the world, it was Covax, there were other countries we had commitments with, we We had taken advance money from them, we had to return some of that money and also convince other world leaders that there was really no other option at that time.’ Poonawalla said that it was really difficult for everyone to accept it, but gradually when they realized what was happening in India, everyone was really supportive and understanding.


#Covishield #Approval #EMA #Covishield #Poonawalla #confident #EMA #approval #Covishield #month #SII #CEO #Adar #Poonawalla #Confident #EMA #approval #Covishield #month

Leave a Reply

Your email address will not be published. Required fields are marked *